Iiia Iiib News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab relapse.

United statesGrand viewIiia iiibMike moyerGabriel morrisPolina stepenskyLos angelesIlya rachmanExchange commissionInternational myeloma society annual meetingImmix biopharma incInternational myeloma working groupInternational myeloma society annualNexcella incCompany contactView research

Nexcella Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Nexcella Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesGrand viewIlya rachmanIiia iiibMike moyerPolina stepenskyGabriel morrisLos angelesInternational myeloma society annualNexcella incView researchInternational myeloma working groupCompany contactInternational myeloma society annual meetingExchange commissionAnnounces complete response

Nexcella Announces Complete Response in 9th

100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab.

Grand viewUnited statesIlya rachmanIiia iiibGabriel morrisLos angelesPolina stepenskyMike moyerInternational myeloma society annualNexcella incExchange commissionCompany contactInternational myeloma working groupInternational myeloma society annual meetingView researchHadassah medical organization

Immix Biopharma (IMMX) Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Immix Biopharma (IMMX) Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Gabriel morrisIlya rachmanPolina stepenskyIiia iiibView researchImmix biopharma incInternational myeloma society annual meetingInternational myeloma society annualInternational myeloma working groupImmix biopharmaHadassah medical organizationBone marrow transplantationChief executive officerChief financial officerBiopharma announces complete responseUniform response

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

100% overall response rate and 67% complete response rate observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff100% .

Grand viewUnited statesMike moyerGabriel morrisPolina stepenskyIiia iiibIlya rachmanLos angelesInternational myeloma society annual meetingHadassah medical organizationDepartment of bone marrow transplantationInternational myeloma working groupInternational myeloma society annualGlobenewswire incCompany contactImmix biopharma inc